caa a22 4500 445338881 CHVBK 20180317142805.0 cr unu---uuuuu 170323e20111201xx s 000 0 eng 10.1245/s10434-011-1847-4 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1847-4 Survival and Quality of Life of Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Interferon-Based Chemoradiation: A Phase II Trial [Elektronische Daten] [Matthew Katz, Robert Wolff, Christopher Crane, Gauri Varadhachary, Milind Javle, E. Lin, Douglas Evans, Jeffrey Lee, Jason Fleming, Peter Pisters] Purpose: We conducted a phase II trial to assess the survival duration and quality of life of patients who received adjuvant interferon-based chemoradiation for pancreatic adenocarcinoma after pancreaticoduodenectomy. Methods: Patients with a performance status of 0 or 1 were enrolled to receive interferon-alfa-2b (3 million units MWF), cisplatin (30mg/m2, 6 doses) and 5-fluorouracil (5-FU; 175mg/m2/day), concurrent with external-beam radiation (50.4Gy) and followed by 2 courses of systemic 5-FU. The protocol was modified to include an optional 9day break in the middle of chemoradiation. Quality of life was assessed by use of validated instruments. Results: Twenty-eight patients were eligible for analysis. The operation of 15 (54%) patients was performed at other institutions. All patients had T3 tumors, 22 (79%) had positive lymph nodes and 4 (14%) had positive (R1) margins. 24 (86%) patients completed therapy. In all, 25 (89%) patients experienced grade 3 toxicity and 3 (11%) patients were hospitalized. The most common grade 3 events were leukopenia (15, 54%) and neutropenia (12, 43%). No grade 4 toxicity occurred. Overall quality of life decreased during chemoradiation but returned to baseline thereafter and was stable throughout surveillance. 19 patients have died; the median follow-up of the 9 survivors is 62months. The median OS duration of treated patients was 42.3 (95% confidence interval 30.5-54.2) months. Conclusions: Adjuvant interferon-based chemoradiation can be delivered safely and tolerably—though with substantial reversible toxicity—to patients of good performance status at an experienced cancer center. Therapy may be associated with an improvement in overall survival. Society of Surgical Oncology, 2011 Katz Matthew Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut Wolff Robert Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut Crane Christopher Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut Varadhachary Gauri Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut Javle Milind Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut Lin E. Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut Evans Douglas Department of Surgery, The Medical College of Wisconsin, Milwaukee, USA aut Lee Jeffrey Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut Fleming Jason Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut Pisters Peter Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut Annals of Surgical Oncology Springer-Verlag 18/13(2011-12-01), 3615-3622 1068-9265 18:13<3615 2011 18 10434 https://doi.org/10.1245/s10434-011-1847-4 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1847-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Katz Matthew Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut NATIONALLICENCE 700 1- Wolff Robert Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut NATIONALLICENCE 700 1- Crane Christopher Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut NATIONALLICENCE 700 1- Varadhachary Gauri Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut NATIONALLICENCE 700 1- Javle Milind Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut NATIONALLICENCE 700 1- Lin E. Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut NATIONALLICENCE 700 1- Evans Douglas Department of Surgery, The Medical College of Wisconsin, Milwaukee, USA aut NATIONALLICENCE 700 1- Lee Jeffrey Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut NATIONALLICENCE 700 1- Fleming Jason Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut NATIONALLICENCE 700 1- Pisters Peter Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, USA aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/13(2011-12-01), 3615-3622 1068-9265 18:13<3615 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer